Therapy April 12 th , 2016 Manny Ribeiro, MD Larry - - PowerPoint PPT Presentation

therapy
SMART_READER_LITE
LIVE PREVIEW

Therapy April 12 th , 2016 Manny Ribeiro, MD Larry - - PowerPoint PPT Presentation

Therapy April 12 th , 2016 Manny Ribeiro, MD Larry Young, MD Objectives The evidence-based medicine cycle Start with a case scenario Ask the clinical question Critical appraisal Allocation concealment


slide-1
SLIDE 1

Therapy

April 12th, 2016 Manny Ribeiro, MD Larry Young, MD

slide-2
SLIDE 2

Objectives

 The evidence-based medicine cycle  Start with a case scenario  Ask the clinical question  Critical appraisal

  • Allocation concealment
  • Intention-to-treat
  • Blinding
  • Follow-up

 Results: making the math simple!

slide-3
SLIDE 3

THE PATIENT ASSESS ASK ACQUIRE APPLY APPRAISE

Evidence- based Medicine Cycle

The 5 A’s

slide-4
SLIDE 4

Case scenario

 A 67-year-old man presented with productive cough and fever for 3 days  Past medical history of coronary artery disease, with a myocardial infarction two years prior  Heavy smoker, 2 packs of cigarettes per day for 50 years (100 pack-year)

slide-5
SLIDE 5

Bad pneumonia!

slide-6
SLIDE 6

 Also had a new myocardial infarction

  • Echocardiogram with a drop in

ejection fraction to 46% and new segmental wall motion abnormality

Case scenario

slide-7
SLIDE 7
slide-8
SLIDE 8
slide-9
SLIDE 9
slide-10
SLIDE 10
slide-11
SLIDE 11

His daughter’s request

“Please start something for my father to quit smoking before he goes home, otherwise he will just go back to it right after discharge.”

slide-12
SLIDE 12

This sounds like PICOTT... Can we PICOTT this? Yes, this is “PICOTT”able!

slide-13
SLIDE 13

P I C O T T

Clinical question formation

  • pulation

ntervention

  • mparison

utcome ype of Question ype of (ideal) study design

slide-14
SLIDE 14

P I C O T T

Clinical question

Smokers admitted to the hospital Inpatient strategies for smoking cessation No/other strategies Quit rate, pneumonia, myocardial infarction Therapy question Randomized controlled trial

slide-15
SLIDE 15

Search strategy

slide-16
SLIDE 16
slide-17
SLIDE 17
slide-18
SLIDE 18

Critical appraisal

= Randomized Controlled Trial

slide-19
SLIDE 19

Goals of randomization

P

R Treatment Control Prognosis X Prognosis X

 To keep all known and unknown prognostic variables evenly distributed between the groups

Outcome A Outcome B

slide-20
SLIDE 20

Group C Group D Group A Group B

slide-21
SLIDE 21

Allocation concealment

slide-22
SLIDE 22

Our population YOU!

slide-23
SLIDE 23

List generation

Head: Allowed to ask questions (A) Tail: NOT Allowed to ask questions (NA)

slide-24
SLIDE 24

Allocation concealment

 The person who is enrolling participants cannot know, predict, or manipulate the list  Trials with inappropriate allocation concealment are associated with larger estimates of treatment effect

slide-25
SLIDE 25

Allocation concealment

P O

R

List generation Allocation concealment

slide-26
SLIDE 26

Intention-to-treat

 AKA: Were patients analyzed in the groups to which they were randomized? Teaching method 1

slide-27
SLIDE 27

Dead Alive Alive Dead Dead Alive Dead Alive R Treatment 1 Treatment 2

slide-28
SLIDE 28

Dead Alive Alive Dead Dead Alive Dead Alive R Treatment 1 Treatment 2

slide-29
SLIDE 29

Dead Alive Alive Dead Dead Alive Dead Alive Dead Alive Alive Dead Dead Alive Dead Alive R Treatment 1 Treatment 2

slide-30
SLIDE 30

Intention-to-treat

Cerebro- vascular disease

R

Surgery + ASA ASA 200 100 100 Stroke Stroke 10 10 Stroke Stroke 10 10 Surgery Per Protocol 10/90 = 11% 20/100 = 20% ITT 20/100 = 20% 20/100 = 20%

RD = 9% RD = 0%

 Teaching method 2

slide-31
SLIDE 31

Intention-to-treat… Why??

 Preserves balance between the groups  Reflects real life

slide-32
SLIDE 32

Blinding

Patient Researcher

2 volunteers!

slide-33
SLIDE 33

Shhhhhhh!!

slide-34
SLIDE 34

Blinding

P O

R

List generation Allocation concealment

Blinding

slide-35
SLIDE 35

Blinding

 Trials with inappropriate blinding are also associated with larger estimates

  • f effect, but not as much as with

inappropriate allocation concealment

slide-36
SLIDE 36

Allocation Concealment Blinding Who? Enroller Patients, caregivers, data collectors, adjudicators, analysts What? The list Group assignments When? Part of randomization After randomization

Allocation Concealment x blinding

slide-37
SLIDE 37

Follow-up

 Patients who are lost often have different prognoses from those who are retained  Strategies to deal with lost to follow up: last observation carried forward, worst-case scenario  The best solution is to assure a good follow up

slide-38
SLIDE 38

Therapy Math

slide-39
SLIDE 39

All-cause hospital admissions

Step 2: Subtract: Step 3: Divide: Step 1: Intensive Usual 23% 41% 41% – 23% = 18% 23% / 41% = 0.56 Risk difference Risk ratio

slide-40
SLIDE 40

Number Needed to Treat

 What is the risk difference of 18% telling you?

In order to save 18, you needed to treat 100 In order to save 1, how many do you need to treat? Formula NNT: 100 / RD

slide-41
SLIDE 41

Number Needed to Treat

 Formula: NNT = 100 / RD NNT = 100 / 18 = 5.5 NNT = 6  You needed to treat 6 patients in

  • rder to prevent one extra

hospitalization in 2 years

slide-42
SLIDE 42

Relative Risk Reduction

 Teaching method 1

20 By how much (in %) did I reduce? Answer: 25% 15

slide-43
SLIDE 43

All-cause hospital admissions

Step 2: Subtract: Step 3: Divide: Step 1: Intensive Usual 23% 41% 41% – 23% = 18% 23% / 41% = 0.56 Risk difference Risk ratio

slide-44
SLIDE 44

Relative Risk Reduction

 Teaching method 2

Formula: RRR = 1 - RR Intensive Usual 23% 41% 23% / 41% = 0.56 Risk ratio

slide-45
SLIDE 45

Relative Risk Reduction

 Teaching method 2

Formula: RRR = 1 - RR Intensive Usual 23% 41% 23% / 41% = 0.56 Risk ratio 41% 41% / 41% = 1

slide-46
SLIDE 46

Relative Risk Reduction

 Teaching method 2

Formula: RRR = 1 - RR Intensive Usual 23% 41% 23% / 41% = 0.56 Risk ratio 1 RRR = 0.44 (44%)

slide-47
SLIDE 47

Math time!

slide-48
SLIDE 48

Mortality

Intensive Usual 2.8% 12% Risk difference: 9.2% Risk Ratio: 0.23 NNT: 11 RRR: 0.77 (77%)

slide-49
SLIDE 49

Take-home points

 The evidence-based medicine cycle: everything starts and ends with a patient  Improper allocation concealment can

  • verestimate the effect size

 For therapy papers, ITT is preferred to per-protocol analysis  Look for who was blinded in the study  Make the math simple! Remember to subtract and divide!

slide-50
SLIDE 50

Teaching Take-home Points

  • What strategies did we use to teach

these concepts?

slide-51
SLIDE 51

Teaching Take-home Points

 Real clinical case – start with a patient.  Clinical question related to different specialties, and even non-medical learners  Group activities  Pre-mark article – saves time; reduces stress  Imperfect articles (you can teach with them)  Interactivity  Different teaching strategies (visual learners, math lovers)  Simplicity: one step at a time, with “no man left behind”  Triage: you can’t do it all

slide-52
SLIDE 52

Back to our patient…

 One year after discharge:

slide-53
SLIDE 53

Thank you!